Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPX159 crossover study in adults with restless legs syndrome
ACTRN12608000558325Phase 2Completed
- Sponsor
- Impax Pharmaceuticals
- Start
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of IPX159 in restless legs syndrome (RLS) (2 arms), sponsored by Impax Pharmaceuticals. Primary endpoints: Polysomnography assessment of periodic limb movements and sleep quality and International Restless Legs Syndrome Study Group Questionnaire. Started Feb 2009; status: completed.
02
Drugs
IPX159
03
Conditions
restless legs syndrome (RLS)
Beyond the preview
Go deeper on ACTRN12608000558325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12608000558325.